Trial Outcomes & Findings for Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children (NCT NCT00525174)

NCT ID: NCT00525174

Last Updated: 2016-07-13

Results Overview

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

186 participants

Primary outcome timeframe

24 weeks

Results posted on

2016-07-13

Participant Flow

Eligibility criteria included age 3 to \<10 years, visual acuity in the amblyopic eye 20/40 to 20/80, fellow eye visual acuity of 20/40 or better, interocular acuity difference of 3 or more lines, and the presence or history of strabismus and/or anisometropia.

At enrollment, subjects were required to have been wearing spectacles with optimal correction for a minimum of 16 weeks or until stability of visual acuity was documented (no improvement in amblyopic visual acuity at 2 consecutive visits at least 4 weeks apart).

Participant milestones

Participant milestones
Measure
Patching
2 hours daily patching of the sound eye plus one hour near activities while patching
Bangerter Filters
Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
Overall Study
STARTED
97
89
Overall Study
COMPLETED
88
81
Overall Study
NOT COMPLETED
9
8

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patching
n=97 Participants
2 hours daily patching of the sound eye plus one hour near activities while patching
Bangerter Filters
n=89 Participants
Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
Total
n=186 Participants
Total of all reporting groups
Age, Continuous
6.3 years
STANDARD_DEVIATION 1.62 • n=99 Participants
6.3 years
STANDARD_DEVIATION 1.67 • n=107 Participants
6.3 years
STANDARD_DEVIATION 1.64 • n=206 Participants
Age, Customized
3 to <7 years
62 participants
n=99 Participants
57 participants
n=107 Participants
119 participants
n=206 Participants
Age, Customized
7 to <10 years
35 participants
n=99 Participants
32 participants
n=107 Participants
67 participants
n=206 Participants
Sex: Female, Male
Female
48 Participants
n=99 Participants
36 Participants
n=107 Participants
84 Participants
n=206 Participants
Sex: Female, Male
Male
49 Participants
n=99 Participants
53 Participants
n=107 Participants
102 Participants
n=206 Participants
Race/Ethnicity, Customized
White
67 participants
n=99 Participants
69 participants
n=107 Participants
136 participants
n=206 Participants
Race/Ethnicity, Customized
African-American
13 participants
n=99 Participants
1 participants
n=107 Participants
14 participants
n=206 Participants
Race/Ethnicity, Customized
Hispanic or Latino
11 participants
n=99 Participants
15 participants
n=107 Participants
26 participants
n=206 Participants
Race/Ethnicity, Customized
Asian
3 participants
n=99 Participants
0 participants
n=107 Participants
3 participants
n=206 Participants
Race/Ethnicity, Customized
More than 1 race
2 participants
n=99 Participants
3 participants
n=107 Participants
5 participants
n=206 Participants
Race/Ethnicity, Customized
Unknown / not reported
1 participants
n=99 Participants
1 participants
n=107 Participants
2 participants
n=206 Participants
Region of Enrollment
United States
97 participants
n=99 Participants
89 participants
n=107 Participants
186 participants
n=206 Participants
Prior treatment for amblyopia at enrollment
None
83 participants
n=99 Participants
72 participants
n=107 Participants
155 participants
n=206 Participants
Prior treatment for amblyopia at enrollment
Patching
8 participants
n=99 Participants
5 participants
n=107 Participants
13 participants
n=206 Participants
Prior treatment for amblyopia at enrollment
Atropine
2 participants
n=99 Participants
3 participants
n=107 Participants
5 participants
n=206 Participants
Prior treatment for amblyopia at enrollment
Patching and atropine
4 participants
n=99 Participants
9 participants
n=107 Participants
13 participants
n=206 Participants
Cause of amblyopia
Strabismus
27 participants
n=99 Participants
23 participants
n=107 Participants
50 participants
n=206 Participants
Cause of amblyopia
Anisometropia
42 participants
n=99 Participants
39 participants
n=107 Participants
81 participants
n=206 Participants
Cause of amblyopia
Strabismus and anisometropia
28 participants
n=99 Participants
27 participants
n=107 Participants
55 participants
n=206 Participants
Distance visual acuity in amblyopic eye
20/80 (0.62 - 0.56 logMAR) (worse)
23 participants
n=99 Participants
16 participants
n=107 Participants
39 participants
n=206 Participants
Distance visual acuity in amblyopic eye
20/63 (0.54 - 0.46 logMAR)
31 participants
n=99 Participants
27 participants
n=107 Participants
58 participants
n=206 Participants
Distance visual acuity in amblyopic eye
20/50 (0.44 - 0.36 logMAR)
22 participants
n=99 Participants
24 participants
n=107 Participants
46 participants
n=206 Participants
Distance visual acuity in amblyopic eye
20/40 (0.34 - 0.28 logMAR) (best)
21 participants
n=99 Participants
22 participants
n=107 Participants
43 participants
n=206 Participants
Mean (SD) Distance Visual Acuity in Amblyopic Eye
0.46 logMAR
STANDARD_DEVIATION 0.10 • n=99 Participants
0.44 logMAR
STANDARD_DEVIATION 0.10 • n=107 Participants
0.45 logMAR
STANDARD_DEVIATION 0.10 • n=206 Participants
Distance visual acuity in fellow eye
20/40 (0.32 to 0.26 logMAR) (worse)
2 participants
n=99 Participants
3 participants
n=107 Participants
5 participants
n=206 Participants
Distance visual acuity in fellow eye
20/32 (0.24 to 0.16 logMAR)
16 participants
n=99 Participants
9 participants
n=107 Participants
25 participants
n=206 Participants
Distance visual acuity in fellow eye
20/25 (0.14 to 0.06 logMAR)
17 participants
n=99 Participants
19 participants
n=107 Participants
36 participants
n=206 Participants
Distance visual acuity in fellow eye
20/20 (0.04 to -0.04 logMAR)
42 participants
n=99 Participants
40 participants
n=107 Participants
82 participants
n=206 Participants
Distance visual acuity in fellow eye
20/16 (-0.06 to -0.14 logMAR) (best)
20 participants
n=99 Participants
18 participants
n=107 Participants
38 participants
n=206 Participants
Mean (SD) Distance Visual Acuity in Fellow Eye
0.04 logMAR
STANDARD_DEVIATION 0.10 • n=99 Participants
0.03 logMAR
STANDARD_DEVIATION 0.10 • n=107 Participants
0.04 logMAR
STANDARD_DEVIATION 0.10 • n=206 Participants
Intereye acuity difference
4.2 logMAR line
STANDARD_DEVIATION 1.1 • n=99 Participants
4.1 logMAR line
STANDARD_DEVIATION 1.1 • n=107 Participants
4.1 logMAR line
STANDARD_DEVIATION 1.1 • n=206 Participants
Spherical equivalent in amblyopic eye
<0.00
3 diopter
n=99 Participants
8 diopter
n=107 Participants
11 diopter
n=206 Participants
Spherical equivalent in amblyopic eye
0 to < +1.00
2 diopter
n=99 Participants
2 diopter
n=107 Participants
4 diopter
n=206 Participants
Spherical equivalent in amblyopic eye
+1.00 to < +2.00
8 diopter
n=99 Participants
1 diopter
n=107 Participants
9 diopter
n=206 Participants
Spherical equivalent in amblyopic eye
+2.00 to < +3.00
6 diopter
n=99 Participants
10 diopter
n=107 Participants
16 diopter
n=206 Participants
Spherical equivalent in amblyopic eye
+3.00 to < +4.00
10 diopter
n=99 Participants
13 diopter
n=107 Participants
23 diopter
n=206 Participants
Spherical equivalent in amblyopic eye
>= +4.00
68 diopter
n=99 Participants
55 diopter
n=107 Participants
123 diopter
n=206 Participants
Mean (SD) spherical equivalent in amblyopic eye
4.41 diopter
STANDARD_DEVIATION 2.21 • n=99 Participants
4.15 diopter
STANDARD_DEVIATION 2.57 • n=107 Participants
4.29 diopter
STANDARD_DEVIATION 2.38 • n=206 Participants
Spherical equivalent in fellow eye
<0.00
1 diopter
n=99 Participants
5 diopter
n=107 Participants
6 diopter
n=206 Participants
Spherical equivalent in fellow eye
0 to < +1.00
18 diopter
n=99 Participants
16 diopter
n=107 Participants
34 diopter
n=206 Participants
Spherical equivalent in fellow eye
+1.00 to < +2.00
25 diopter
n=99 Participants
21 diopter
n=107 Participants
46 diopter
n=206 Participants
Spherical equivalent in fellow eye
+2.00 to < +3.00
13 diopter
n=99 Participants
12 diopter
n=107 Participants
25 diopter
n=206 Participants
Spherical equivalent in fellow eye
+3.00 to < +4.00
8 diopter
n=99 Participants
13 diopter
n=107 Participants
21 diopter
n=206 Participants
Spherical equivalent in fellow eye
>= +4.00
32 diopter
n=99 Participants
22 diopter
n=107 Participants
54 diopter
n=206 Participants
Mean (SD) spherical equivalent in fellow eye
2.81 diopter
STANDARD_DEVIATION 2.14 • n=99 Participants
2.49 diopter
STANDARD_DEVIATION 2.13 • n=107 Participants
2.66 diopter
STANDARD_DEVIATION 2.14 • n=206 Participants

PRIMARY outcome

Timeframe: 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/63 (0.54 to 0.46 logMAR)
7 participants
8 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/50 (0.44 to 0.36 logMAR)
5 participants
12 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/40 (0.34 to 0.26 logMAR)
19 participants
19 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/16 (-0.06 to -0.14 logMAR) (best)
0 participants
4 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/125 (0.84 to 0.76 logMAR) (worse)
1 participants
0 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/100 (0.74 to 0.66 logMAR)
3 participants
0 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/80 (0.64 to 0.56 logMAR)
3 participants
1 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/32 (0.24 to 0.16 logMAR)
14 participants
20 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/25 (0.14 to 0.06 logMAR)
20 participants
17 participants
Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks
20/20 (0.04 to -0.04 logMAR)
9 participants
7 participants

PRIMARY outcome

Timeframe: 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Mean (SD) of Amblyopic Eye Visual Acuity at 24 Weeks
0.25 logMAR
Standard Deviation 0.19
0.23 logMAR
Standard Deviation 0.16

PRIMARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). 'Worse' indicates acuity at 24 weeks is worse than acuity at baseline; 'Better' indicates acuity at 24 weeks is better than acuity at baseline.

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
>= 3 lines worse
1 participants
0 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
2 lines worse
2 participants
0 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
1 line worse
5 participants
1 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
0 lines
8 participants
4 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
1 line better
12 participants
19 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
2 lines better
20 participants
27 participants
Distribution of Change in Amblyopic Eye Visual Acuity Scores From Baseline to 24 Weeks
>=3 lines better
33 participants
37 participants

PRIMARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). Change from baseline to 24 weeks was calculated. A positive difference indicates improvement (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Mean Change in Amblyopic Eye Visual Acuity From Baseline to 24 Weeks
1.9 logMAR line
Standard Deviation 1.6
2.3 logMAR line
Standard Deviation 1.3

SECONDARY outcome

Timeframe: 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). A positive interocular difference indicates worse acuity in the amblyopic eye (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Mean Interocular Difference at 24 Weeks
2.3 logMAR line
Standard Deviation 2.0
2.3 logMAR line
Standard Deviation 1.5

SECONDARY outcome

Timeframe: 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). A positive interocular difference indicates worse acuity in the amblyopic eye (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=87 Participants
Distribution of Subjects With Interocular Difference <1 logMAR Line at 24 Weeks
15 participants
10 participants

SECONDARY outcome

Timeframe: 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=87 Participants
Distribution of Subjects With >= 20/25 Amblyopic Eye Visual Acuity at 24 Weeks
29 participants
27 participants

SECONDARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). Change from baseline to 24 weeks was calculated. A positive difference indicates improvement (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=87 Participants
Distribution of Subjects With 3 or More Lines of Improvement
31 participants
31 participants

SECONDARY outcome

Timeframe: 24 weeks

The distribution of the number of participants in each patient characteristic category at the 24-week outcome examination was found (for example, the number of participants at 24 weeks who were 3 to \<5 years old at the time of enrollment).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Female
34 participants
43 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Male
47 participants
45 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
White, non-Hispanic
63 participants
61 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Non-white or Hispanic
17 participants
26 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Age at enrollment: 3 to <5 yrs
21 participants
23 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Distance VA in amblyopic eye: 20/40 (best)
21 participants
20 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Age at enrollment: 5 to <7 yrs
31 participants
34 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Age at enrollment: 7 to <10 yrs
29 participants
31 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Prior treatment for amblyopia: No
65 participants
75 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Prior treatment for amblyopia: Yes
16 participants
13 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Cause of amblyopia: Strabismus
21 participants
23 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Cause of amblyopia: Anisometropia
36 participants
39 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Cause of amblyopia: Strabismus and anisometropia
24 participants
26 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Distance VA in amblyopic eye: 20/80 (worse)
15 participants
22 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Distance VA in amblyopic eye: 20/63
25 participants
29 participants
Distribution of Patient Characteristics at the 24-week Outcome Exam.
Distance VA in amblyopic eye: 20/50
20 participants
17 participants

SECONDARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). Change from baseline to 24 weeks was calculated. A positive difference indicates improvement (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Female
2.1 logMAR line
Standard Deviation 1.7
2.4 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Male
1.7 logMAR line
Standard Deviation 1.6
2.2 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
White, non-Hispanic
1.8 logMAR line
Standard Deviation 1.7
2.3 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Non-white or Hispanic
2.1 logMAR line
Standard Deviation 1.4
2.4 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Age at enrollment: 3 to <5 yrs
2.1 logMAR line
Standard Deviation 1.9
2.7 logMAR line
Standard Deviation 1.4
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Age at enrollment: 5 to <7 yrs
2.1 logMAR line
Standard Deviation 1.7
2.5 logMAR line
Standard Deviation 1.2
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Age at enrollment: 7 to <10 yrs
1.5 logMAR line
Standard Deviation 1.3
1.8 logMAR line
Standard Deviation 1.2
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Prior treatment for amblyopia: No
1.9 logMAR line
Standard Deviation 1.7
2.4 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Prior treatment for amblyopia: Yes
2.0 logMAR line
Standard Deviation 1.4
1.7 logMAR line
Standard Deviation 1.0
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Cause of amblyopia: Strabismus
2.2 logMAR line
Standard Deviation 1.5
2.4 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Cause of amblyopia: Anisometropia
1.5 logMAR line
Standard Deviation 1.7
2.4 logMAR line
Standard Deviation 1.4
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Distance VA in amblyopic eye: 20/80 (worse)
2.3 logMAR line
Standard Deviation 2.0
2.3 logMAR line
Standard Deviation 1.3
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Distance VA in amblyopic eye: 20/63
1.8 logMAR line
Standard Deviation 1.7
2.5 logMAR line
Standard Deviation 1.5
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Distance VA in amblyopic eye: 20/50
1.7 logMAR line
Standard Deviation 1.7
2.3 logMAR line
Standard Deviation 1.4
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Distance VA in amblyopic eye: 20/40 (best)
1.9 logMAR line
Standard Deviation 1.0
2.0 logMAR line
Standard Deviation 1.1
Mean and SD of Change in Visual Acuity in the Amblyopic Eye From Baseline to 24-Week Outcome Examination According to Patient Characteristics
Cause of amblyopia: Strabismus and anisometropia
2.2 logMAR line
Standard Deviation 1.5
2.1 logMAR line
Standard Deviation 1.2

SECONDARY outcome

Timeframe: Baseline to 24 weeks

The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc. It is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score \>800 (the worst), 800, 400, 200, 100, 60, or 40 (the best). If two shapes are identified correctly the patient moves to the next lower level. A failed test occurs when the patient cannot identify any shapes. A change of 1 level is a movement of 1 step in the scale (decrease shows improvement - ex. 100 to 60 is 1 level improved).

Outcome measures

Outcome measures
Measure
Bangerter
n=76 Participants
Patching
n=80 Participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-Week Outcome by Treatment Group: All Subjects
>=2 levels improved
12 participants
15 participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-Week Outcome by Treatment Group: All Subjects
Within 1 level
61 participants
58 participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-Week Outcome by Treatment Group: All Subjects
>=2 levels worsened
3 participants
7 participants

SECONDARY outcome

Timeframe: Baseline to 24 weeks

The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc. It is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score \>800 (the worst), 800, 400, 200, 100, 60, or 40 (the best). If two shapes are identified correctly the patient moves to the next lower level. A failed test occurs when the patient cannot identify any shapes. A change of 1 level is a movement of 1 step in the scale (decrease shows improvement - ex. 100 to 60 is 1 level improved).

Outcome measures

Outcome measures
Measure
Bangerter
n=33 Participants
Patching
n=34 Participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-week Outcome by Treatment Group: Subjects With Anisometropia and No Strabismus
>=2 levels improved
7 participants
9 participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-week Outcome by Treatment Group: Subjects With Anisometropia and No Strabismus
Within 1 level
25 participants
21 participants
Distribution of Change in Randot Preschool Stereoacuity From Baseline to 24-week Outcome by Treatment Group: Subjects With Anisometropia and No Strabismus
>=2 levels worsened
1 participants
4 participants

SECONDARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). Change from baseline to 24 weeks was calculated. A positive difference indicates improvement (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
3 lines or worse
0 participants
0 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
2 lines worse
1 participants
5 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
1 line worse
17 participants
8 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
0 lines
39 participants
40 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
1 line better
20 participants
23 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
2 lines better
4 participants
11 participants
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
3 lines or better
0 participants
1 participants

SECONDARY outcome

Timeframe: Baseline to 24 weeks

Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) testing protocol resulting in a Snellen acuity score for 3 to \<7 year olds; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds, resulting in a letter score that could range from 0 to 97 letters (0 worst; 97 best). Scores were converted to log of minimum angle of resolution (logMAR)(lower logMAR indicates better score). Change from baseline to 24 weeks was calculated. A positive difference indicates improvement (one logMAR line = 5 letters or one Snellen line).

Outcome measures

Outcome measures
Measure
Bangerter
n=81 Participants
Patching
n=88 Participants
Mean Change in Fellow Eye Visual Acuity From Baseline to 24 Weeks
0.09 logMAR line
Standard Deviation 0.84
0.36 logMAR line
Standard Deviation 1.1

SECONDARY outcome

Timeframe: 6 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family. Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores were summed and averaged for each individual (total sums could range from 0 to 90; means could range from 0 to 5). A mean across all individuals was computed from the individual means.

Outcome measures

Outcome measures
Measure
Bangerter
n=79 Participants
Patching
n=81 Participants
Impact of Treatment on Patient and Family at 6 Weeks
2.1 Units on a scale
Standard Deviation 1.1
2.3 Units on a scale
Standard Deviation 1.0

SECONDARY outcome

Timeframe: 24 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family. Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores were summed and averaged for each individual (total sums could range from 0 to 90; means could range from 0 to 5). A mean across all individuals was computed from the individual means.

Outcome measures

Outcome measures
Measure
Bangerter
n=75 Participants
Patching
n=75 Participants
Impact of Treatment on Patient and Family at 24 Weeks
1.9 Units on a scale
Standard Deviation 1.0
2.3 Units on a scale
Standard Deviation 1.1

SECONDARY outcome

Timeframe: 6 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (8 of these questions pertain to adverse effects of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 8 questions were summed and averaged for each individual (total sums could range from 0 to 40). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=79 Participants
Patching
n=81 Participants
Adverse Effects of Treatment on Patient and Family at 6 Weeks
2.2 Units on a scale
Standard Deviation 0.7
2.2 Units on a scale
Standard Deviation 0.6

SECONDARY outcome

Timeframe: 24 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (8 of these questions pertain to adverse effects of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 8 questions were summed and averaged for each individual (total sums could range from 0 to 40). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=75 Participants
Patching
n=75 Participants
Adverse Effects of Treatment on Patient and Family at 24 Weeks
1.9 Units on a scale
Standard Deviation 0.7
2.2 Units on a scale
Standard Deviation 0.6

SECONDARY outcome

Timeframe: 6 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (7 of these questions pertain to compliance of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 7 questions were summed and averaged for each individual (total sums could range from 0 to 35). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=79 Participants
Patching
n=81 Participants
Compliance With Treatment at 6 Weeks
2.3 Units on a scale
Standard Deviation 1.0
2.5 Units on a scale
Standard Deviation 0.8

SECONDARY outcome

Timeframe: 24 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (7 of these questions pertain to compliance of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 7 questions were summed and averaged for each individual (total sums could range from 0 to 35). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=75 Participants
Patching
n=75 Participants
Compliance With Treatment at 24 Weeks
2.1 Units on a scale
Standard Deviation 0.9
2.6 Units on a scale
Standard Deviation 0.9

SECONDARY outcome

Timeframe: 6 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (2 of these questions pertain to social stigma of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 2 questions were summed and averaged for each individual (total sums could range from 0 to 10). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=79 Participants
Patching
n=81 Participants
Social Stigma From Treatment at 6 Weeks
1.7 Units on a scale
Standard Deviation 0.6
2.4 Units on a scale
Standard Deviation 0.9

SECONDARY outcome

Timeframe: 24 weeks

The Parental Amblyopia Treatment Index consists of 18 likert-type questions evaluating the impact of treatment on the patient and family (2 of these questions pertain to social stigma of treatment). Questions are answered on a scale from 'Strongly Disagree' to 'Strongly Agree.' For analysis, values were coded numerically with integers from 5 (strongly agree) to 1 (strongly disagree) (0 was assigned to 'non-applicable' answers). The scores for these 2 questions were summed and averaged for each individual (total sums could range from 0 to 10). A mean across all individuals was computed.

Outcome measures

Outcome measures
Measure
Bangerter
n=75 Participants
Patching
n=75 Participants
Social Stigma From Treatment at 24 Weeks
1.6 Units on a scale
Standard Deviation 0.7
2.4 Units on a scale
Standard Deviation 0.8

Adverse Events

Patching

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Bangerter Filters

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Raymond Kraker, MSPH

Jaeb Center for Health Research

Phone: 813-875-8690

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place